Associated Papers
Parkinson's disease-associated mutations in α-synuclein alters its lipid-bound state.
Maltseva S et al.
Biophysical Journal, 2024
Interfacial properties of α-synuclein's Parkinsonian variants.
Mohapatra A et al.
Biophysical Chemistry, 2023
Genotypic-Phenotypic Analysis, Metabolic Profiling and Clinical Correlations in Parkinson's Disease Patients from Tamil Nadu Population, India.
Venkatesan D et al.
Journal of Molecular Neuroscience : Mn, 2022
Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders.
Padilla-Godínez FJ et al.
International Journal of Molecular Sciences, 2021
Different Effects of α-Synuclein Mutants on Lipid Binding and Aggregation Detected by Single Molecule Fluorescence Spectroscopy and ThT Fluorescence-Based Measurements.
Ruf VC et al.
Acs Chemical Neuroscience, 2019
Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
Lima VA et al.
Acs Chemical Neuroscience, 2019
Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
Coskuner-Weber O et al.
International Journal of Molecular Sciences, 2018
Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications.
Ottolini D et al.
Biological Chemistry, 2017
Familial Parkinson disease-associated mutations alter the site-specific microenvironment and dynamics of α-synuclein.
Sahay S et al.
The Journal of Biological Chemistry, 2015
Genetic variants and animal models in SNCA and Parkinson disease.
Deng H et al.
Ageing Research Reviews, 2014
Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice.
Marxreiter F et al.
Neurobiology of Disease, 2013
Α-synuclein misfolding and Parkinson's disease.
Breydo L et al.
Biochimica Et Biophysica Acta, 2012
Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson's disease revealed by solution NMR spectroscopy.
Bodner CR et al.
Biochemistry, 2010
Novel suppressors of alpha-synuclein toxicity identified using yeast.
Liang J et al.
Human Molecular Genetics, 2008
alpha-Synucleinopathy models and human neuropathology: similarities and differences.
Kahle PJ
Acta Neuropathologica, 2008
YGR198w (YPP1) targets A30P alpha-synuclein to the vacuole for degradation.
Flower TR et al.
The Journal of Cell Biology, 2007
Part II: alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease.
Dev KK et al.
Neuropharmacology, 2003
Mouse models of alpha-synucleinopathy and Lewy pathology.
Sommer B et al.
Experimental Gerontology, 2000
Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
Gomez-Isla T et al.
Neurobiology of Aging, 0